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cardiomyopathy but understanding of the mechanisms is incomplete, partly because the roles of speciﬁc TKI target
receptors in the heart are still obscure.Methods Myocardial infarction was induced in mice by permanent ligation of the left anterior descending coronary artery
followed by intramyocardial injection of FLT3 ligand (FL) or vehicle into the infarct border zone. Cardiac morphology
and function were assessed by echocardiography and histological analysis 1 week after infarction. In addition, FLT3
expression and regulation, as well as molecular mechanisms of FLT3 action, were examined in cardiomyocytes
in vitro.Results The intramyocardial injection of FL into the infarct border zone decreased infarct size and ameliorated
post-myocardial infarction remodeling and function in mice. This beneﬁcial effect was associated with reduced
apoptosis, including myocytes in the infarct border zone. Cardiomyocytes expressed functional FLT3, and FLT3
messenger ribonucleic acid and protein were up-regulated under oxidative stress, identifying cardiomyocytes as
FL target cells. FLT3 activation with FL protected cardiomyocytes from oxidative stress–induced apoptosis via an
Akt-dependent mechanism involving Bcl-2 family protein regulation and inhibition of the mitochondrial death
pathway.Conclusions FLT3 is a cytoprotective system in the heart and a potential therapeutic target in ischemic cardiac injury. The
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Table 1
Echocardiographic Measurements at
1-Week Post-Myocardial Infarction
Sham-Operated
Mice (n ¼ 4)
MI-V–Treated
(n ¼ 13)
MI-FL–Treated
(n ¼ 12)
Heart rate (beats/min) 693  23 669  12 638  20
IVSd (mm) 0.85  0.06 0.63  0.08 0.75  0.05
LVPWd (mm) 0.81  0.05 0.72  0.05 0.82  0.02
LVEDD (mm) 2.74  0.11 4.56  0.17* 4.36  0.12*
IVSs (mm) 1.29  0.03 0.75  0.09y 0.92  0.08z
LVPWs (mm) 1.09  0.05 0.79  0.05y 0.92  0.03
LVESD (mm) 1.58  0.06 4.18  0.22* 3.78  0.17*
LVEF (%) 80.3  2.8 24.6  3.6* 35.3  3.9*x
Values are mean  SEM. Compared with sham-operated mice: *p < 0.0001, yp < 0.01, zp < 0.05.
Compared with MI-V, xp < 0.05.
d ¼ diastole; IVS ¼ interventricular septum; LVEDD ¼ left-ventricular end-diastolic diameter;
LVESD ¼ left-ventricular end-systolic diameter; LVEF ¼ left-ventricular ejection fraction;
LVPW ¼ left-ventricular posterior wall; MI-FL ¼ myocardial infarction group treated with recombi-
nant mouse FMS-like tyrosine kinase 3 ligand; MI-V ¼ myocardial infarction group treated with
vehicle; s ¼ systole.
Abbreviations
and Acronyms
EPO = erythropoietin
ERK = extracellular signal-
regulated kinase
G-CSF = granulocyte-colony
stimulating factor
FL = FMS-like tyrosine
kinase 3 ligand
FLT3 = FMS-like tyrosine
kinase 3
H2O2 = hydrogen peroxide
LAD = left anterior
descending
MEK = mitogen-activated
protein kinase
MI-FL = myocardial
infarction group treated with
recombinant mouse FMS-
like tyrosine kinase 3 ligand
MI-V = myocardial infarction
group treated with vehicle
mRNA = messenger
ribonucleic acid
PI3K = phosphatidylinositol
3 kinase
SCF = stem cell factor
TKI = receptor tyrosine
kinase inhibitor
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1012In addition to the hemato-
poietic system, FLT3 (5) and FL
(6) are also expressed in nonhema-
topoieticorgans. Importantly,FLT3
gene and FL gene and protein
expression have been identiﬁed in
whole heart homogenates (5–8),
but the functional relevance of this
expression is unknown. Because
gene expression of FLT3 and FL
are increased after myocardial
infarction (8), we hypothesized
that FLT3/FL play a role in the
ischemic myocardium. It is now
well established that hematopoietic
growth factors participate in the
infarct-related inﬂammatory re-
sponse and may contribute to
the preservation and regeneration
of myocardial tissue. Granulocyte-
colony stimulating factor (G-CSF)
(9), erythropoietin (EPO) (10),
and stem cell factor (SCF) (8) are
markedly increased after myo-
cardial infarction, and their re-
ceptors have been identiﬁed on
cardiomyocytes (G-CSFR;EPOR)
(11,12), endothelial cells (G-CSFR;
EPOR) (13,14), and cardiacprogenitor cells (SCF receptor c-kit) (15). Notably, a direct
cytoprotective effect has been demonstrated for G-CSF,
which decreases infarct size and attenuates cardiac dysfunction
via activation of G-CSFR–coupled pro-survival signaling in
cardiomyocytes (11). However, whether cardiomyocytes
express FLT3 is not known, and the functional relevance of
FLT3/FL regulation in the infarcted heart remains to be
elucidated.
FLT3 is part of the so-called “cancer kinome.” Because
of its high expression levels and the activity-enhancing
mutations associated with acute myelogenous leukemia,
FLT3 has become a prominent drug target. Several receptor
tyrosine kinase inhibitors (TKIs) targeting FLT3 exist,
some of which are already in clinical use (16). Recent
evidence suggests that TKIs inhibiting multiple receptors,
including FLT3, impair cardiac function (17–19). However,
the mechanisms of TKI-associated cardiotoxicity are not
well understood, and identiﬁcation of speciﬁc TKI target
receptors in the heart and knowledge of their roles are
incomplete. In particular, to date, FLT3 was not considered
to play a role in the heart and, whereas experimental
evidence predicts cardiotoxic effects of inhibition for
numerous kinases in the heart (20), no data exist for FLT3.
In the present study, using a mouse model of myocardial
infarction and cultured primary cardiomyocytes, we dem-
onstrate that FLT3 exerts cardioprotective effects in the
ischemic heart.Methods
AdetailedMethods section is available in theOnlineAppendix.
Cell culture. Cardiomyocytes were isolated from hearts of
1 to 3-day-old Sprague-Dawley rats as previously described
(21). For details, please see the Online Appendix.
Myocardial infarction and intramyocardial FL injection.
Myocardial infarction was induced in female C57BL/6J
mice (age 8 to 10 weeks; N ¼ 30) by permanent ligation of
the left anterior descending (LAD) coronary artery as
previously described (22). Mice were randomly assigned to
recombinant mouse FL (MI-FL; n ¼ 15) or vehicle (MI-V;
n ¼ 15) to be injected into the infarct border zone imme-
diately after LAD ligation. Sham-operated mice (n ¼ 4)
served as controls. Three animals died during surgery, 2 of
which were assigned to MI-FL and 1 to MI-V, respectively.
The Online Appendix presents the technical details on
animal surgery and drug injection.
Echocardiography. Echocardiography was performed 1 day
before (baseline) and 1 week after myocardial infarction in-
duction by using a Vevo 2100 high-resolution, small animal
digital ultrasound system (VisualSonics Inc.,Toronto,Ontario,
Canada) equipped with a linear-array transducer operating
at a centerline frequency of 30 MHz. The procedural details
are presented in the Online Appendix.
Statistical methods. Data are presented as mean  SEM.
Statistical analyses were performed with GraphPad Prism
software version 6 (GraphPad Prism Software Inc., La
Jolla, California). The unpaired, 2-tailed Student t test
was used for comparison of 2 groups, 1-way analysis of
variance followed by Newman-Keuls posttesting for com-
parison of all means of 3 groups, or Bonferroni for com-
parison of selected, prespeciﬁed pairs of columns of 4
groups. A p value <0.05 was considered statistically
signiﬁcant.
Study approval. All animal procedures and handling were
in accordance with the guidelines of Harvard Medical
School, the Longwood Medical Area Institutional Animal
Figure 1 FL Decreases Myocardial Infarct Size, Inhibits Apoptosis, and Improves Remodeling in Mice
Mice were subjected to myocardial infarction by permanent ligation of the left anterior descending artery, and infarct size was determined 1 week post-myocardial infarction by
using Masson’s Trichrome staining. (A) Representative cross-sectional heart images from the midpapillary level from vehicle (MI-V)–treated and FMS-like tyrosine kinase
3 ligand (FL)-treated (MI-FL) mice are depicted in the panel. Bar, 1 mm. (B) Quantiﬁcation of infarct size. N ¼ 6/6 for MI-V/MI-FL, respectively. (C) Apoptosis was determined in
the infarct border zone at the midpapillary level by TUNEL (white) and additional immunohistochemical staining of cardiomyocytes (alpha-sarcomeric actinin, red) and nuclear
counterstaining (Hoechst 33342, blue). Representative immunohistochemical image. (D) Quantiﬁcation of apoptotic nuclei in MI-V (n ¼ 13) and MI-FL (n ¼ 12) hearts. (E)
Change in total wall thickness (TWT) as determined echocardiographically as the change of end-diastolic interventricular septum plus posterior wall thickness at 1-week
post-myocardial infarction over baseline in MI-V (n ¼ 13) and MI-FL (n ¼ 12) mice. *p < 0.05 versus MI-V for B, D, and E.
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1013Care and Use Committee, and the National Society for
Medical Research.Results
FL improves post-myocardial infarction remodeling and
function in mice. We ﬁrst examined whether activation of
FLT3 affects myocardial remodeling and function after
myocardial infarction in mice. From the 27 mice who survived
surgery, 1 died at day 6 (MI-V) and 1 at day 7 (MI-FL)
post-myocardial infarction, leaving 13 (MI-V) and 12
(MI-FL) mice for ﬁnal analysis, respectively. Echocardio-
graphy at baseline showed no differences in terms of wallthickness and left ventricular dimensions and function
between groups (Online Table 1). One week after myocar-
dial infarction, left ventricular end-diastolic and end-systolic
diameters were signiﬁcantly increased in both myocardial
infarction groups compared with the sham-operated group
(Table 1). In addition, systolic wall thickness and systolic
function were decreased; this outcome was more pronounced
in the MI-V group, in which left ventricular ejection fraction
was signiﬁcantly lower compared with the MI-FL group.
Myocardial remodeling was further examined by using
histological analysis. Infarct size was signiﬁcantly reduced in
MI-FL hearts compared withMI-V hearts (Figs. 1A and 1B).
The beneﬁcial effect of FL on infarct size was associated with
Figure 2 FLT3 Is Expressed by Cardiomyocytes and Up-regulated in Response to Oxidative Stress
(A) Gene expression of FMS-like tyrosine kinase 3 (FLT3) as assessed by using reverse transcription polymerase chain reaction. FLT3 messenger ribonucleic acid (mRNA) can
be detected in whole heart homogenates of adult (lane 1) and neonatal rats (lane 2) and in primary isolated and cultured cardiomyocytes (lane 3). Lane 4: no complementary
deoxyribonucleic acid (negative control); lane 5: bone marrow (positive control). (B, C) Cultured cardiomyocytes were exposed to endogenous (hypoxia, C; n ¼ 4) and exogenous
(hydrogen peroxide [H2O2], 200 mmol/l, D; n ¼ 3) oxidative stress for 24 h, and mRNA expression of FLT3 over time was measured by using quantitative real-time reverse
transcription polymerase chain reaction. N indicates the number of independent experiments, each obtained from different cell isolates. (D) Flow cytometric analysis of FLT3
protein expression using a phycoerythrin (PE)-conjugated rat anti-mouse CD135 antibody and a PE-conjugated rat IgG2a, kappa isotype; representative read-out of 7 control and
4 (hypoxia) independent experiments. (E) Quantiﬁcation of anti-CD135–associated ﬂuorescence as integral normalized to cell count for 4 matched analyses. *p < 0.05 and
**p < 0.01 versus corresponding control. N indicates the number of independent experiments, each obtained from different cell isolates. SrRNA ¼ small ribosomal ribonucleic
acid.
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1014a signiﬁcantly lower amount of apoptotic nuclei in the infarct
border zone of MI-FL–treated mice compared with MI-V–
treated mice (Figs. 1C and 1D). These histological ﬁndings
are consistent with the echocardiographically documented
decrease in total wall thickness in MI-V hearts as opposed to
MI-FL hearts, in which total wall thickness was maintained
compared with baseline (Fig. 1E). The preservation of totalwall thickness inMI-FL hearts was associated with an increase
in left ventricular end-diastolic diameter comparable to MI-V
hearts (p ¼ NS; data not shown). Taken together, these
ﬁndings imply increased cellularity of the infarcted MI-FL–
treated hearts compared with the untreated (MI-V) hearts,
which may be due, at least in part, to improved cell survival in
the infarct border zone.
Figure 3 FLT3 Stimulation With FL Induces Transient MEK/ERK- and Sustained Akt-Signaling
(A to C) Cultured cardiomyocytes were treated with FL (2 mg/ml) for up to 90 min, and phosphorylation of MEK(Ser217/221) and ERK(Thr202/204) was measured (n ¼ 4).
(D) Similar experiments were performed for assessment of Akt phosphorylation (Ser473) (n ¼ 4). (E) Cultured cardiomyocytes were treated with different doses of FL for 15 min,
and Akt-phosphorylation was determined (n ¼ 3). *p < 0.05, **p< 0.01, and ***p< 0.001 versus corresponding control. N indicates the number of independent experiments,
each obtained from different cell isolates. mFL ¼ recombinant mouse FL, a.u. ¼ arbitrary units; other abbreviations as in Figure 1.
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1015FLT3 is expressed by cardiomyocytes and up-regulated
under oxidative stress. Cardiomyocytes account for >90%
of the myocardial mass and represent the structural substrate
of the contractile function of the heart. Because FL
preserved myocardial tissue and improved postinfarct func-
tion, we sought to determine whether cardiomyocytes
express FLT3 and qualify as FL target cells. Isolated primary
cardiomyocytes were cultured, and FLT3 gene and protein
expression were examined. FLT3 gene was robustly
expressed in whole heart homogenates from neonatal and
adult rats and in cultured cardiomyocytes (Fig. 2A). Using
quantitative real-time reverse transcription polymerase chain
reaction, we found that FLT3 messenger ribonucleic acid
(mRNA) was time dependently up-regulated in response to
endogenous (hypoxia) (Fig. 2B) or exogenous (hydrogen
peroxide [H2O2]) (Fig. 2C) oxidative stress. We further
assessed FLT3 protein expression in cardiomyocytes by ﬂow
cytometry using a phycoerythrin-conjugated monoclonal
antibody against FLT3. These experiments demonstrated
solid immunoreactivity for FLT3 protein, which was absentin the cardiomyocytes incubated with isotype control anti-
body, thus supporting FLT3 expression in cardiomyocytes.
Similar to FLT3 mRNA, oxidative stress also increased the
amount of FLT3 protein after 24 h, which was most
pronounced in cardiomyocytes exposed to hypoxia (Figs. 2D
and 2E). Our ﬁndings are consistent with the increase in
FLT3 mRNA described in the post-myocardial infarction
mouse heart (8) and substantiate the presence of FLT3 in
cardiomyocytes. Its up-regulation under oxidative stress
implies a speciﬁc role of FLT3/FL in the ischemic or
otherwise injured heart.
FLT3 stimulation by recombinant FL induces pro-
survival signaling in cardiomyocytes. FLT3 activation in
early hematopoietic progenitor cells induces Akt and ERK
signaling (2), which improve cell survival by inhibiting
apoptosis (16).Our goalwas to determine if similar pro-survival
pathways are activated in cardiomyocytes in response to FL.
Stimulation of cardiomyocytes with recombinant mouse FL
(mFL) induced phosphorylation of MEK and ERK, which
was transient and peaked at 5 min (Figs. 3A to 3C). FL also
Figure 4
FL Inhibits Oxidative Stress-Induced Cardiomyocyte Apoptosis Via Restoration of the Bax/Bcl-2 Ratio and Inhibition of
Cytochrome c Release
(A) Isolated cardiomyocytes were plated on plastic coverslips and exposed to H2O2 (200 mmol/l, 24 h) with or without FL (2 mg/ml) pretreatment (30 min), and TUNEL staining
was performed. Blue: cell nuclei (4’,6-diamidino-2-phenylindole); green: TUNEL-positive nuclei. Bar, 100 mm. (B) Quantiﬁcation of TUNEL-positive nuclei (n ¼ 4). (C) Cultured
cardiomyocytes were treated with H2O2 (200 mmol/l, 16 h) in the absence or presence of FL (2 mg/ml), and expression of Bax and Bcl-2 protein was measured by using the
Western blot protocol (n ¼ 3). (D to F) Similar experiments as per Figure 4C were performed, and cytosolic cytochrome c (n ¼ 4) and cleaved caspase-3 (n ¼ 9) were determined
by using the Western blot protocol. Erythropoietin was used for its antiapoptotic properties in cardiomyocytes as a positive control. N indicates the number of independent
experiments, each obtained from different cell isolates. Abbreviations as in Figures 1 to 3.
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1016led to a signiﬁcant time- and dose-dependent increase in
Akt-phosphorylation (Figs. 3D and 3E), which was sus-
tained over 90 min. FL-induced Akt-phosphorylation was
FLT3mediated because it was attenuated in cardiomyocytes,
in which FLT3 was down-regulated by FLT3 targeting
small interfering ribonucleic acid (Online Fig. 1). These
ﬁndings support the expression of functional FLT3 on
cardiomyocytes and the FL-induced activation of Akt- and
transient MEK/ERK signaling.
FL protects cardiomyocytes from oxidative stress–
induced apoptosis by inhibiting the mitochondrial death
pathway. Activation of FLT3 improves survival of hema-
topoietic progenitor cells (4). We therefore tested whetherFL exerts antiapoptotic effects in cardiomyocytes under
oxidative stress. Exposure to H2O2 signiﬁcantly increased
the amount of TUNEL-positive cardiomyocytes, and this
increasewas inhibited in the presence of FL (Figs. 4A and 4B).
To examine the molecular mechanism of this antiapoptotic
effect, speciﬁcally the role of the mitochondria, expression
of the pro-apoptotic Bax and the antiapoptotic Bcl-2,
cytochrome c, and cleaved caspase-3 were measured. H2O2
increased Bax while decreasing Bcl-2 expression, and these
H2O2-evoked changes were inhibited in cardiomyocytes pre-
treatedwithFL (Fig. 4C). Similarly,H2O2 enhanced cytosolic
cytochrome c and increased cleaved caspase-3, which were
markedly inhibited by FL (Figs. 4D to 4F).
Figure 5
The FL-Induced Antiapoptotic Effect in
Cardiomyocytes Is Akt-Dependent
(A) Cultured cardiomyocytes were pre-treated with the Akt inhibitor VIII (Akti; 2 to
10 mmol/l) for 30 min before FL was added (2 mg/ml, 15 min), and basal and
FL-induced phosphorylation of Akt and ERK were assessed by using a Western blot
protocol (n ¼ 2). (B) Cardiomyocytes were pre-treated with Akti (2 mmol/l, 30 min),
and FL was added for another 30 min. Cells were then exposed to H2O2
(200 mmol/l), and cytosolic cytochrome c was measured after 16 h (n ¼ 3).
N indicates the number of independent experiments, each obtained from different
cell isolates. Abbreviations as in Figures 1 to 3.
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1017Akt has been shown to prevent apoptosis via inhibition
of mitochondrial cytochrome c release (23). Because FL
produced sustained Akt-phosphorylation in cardiomyocytes,
we tested whether Akt mediates the antiapoptotic effect of
FL by using the Akt inhibitor VIII (Akti). Akti completely
suppressed basal and FL-induced Akt-phosphorylation,
whereas it accentuated both basal and FL-induced ERK
phosphorylation (Fig. 5A). Consistent with our hypothesis,
FL failed to prevent the H2O2-associated release of cyto-
chrome c in the presence of Akti (Fig. 5B), suggesting that
Akt is necessary for the FL-induced cytoprotective effect.
Together, our in vitro ﬁndings identify cardiomyocytes as
FL target cells and demonstrate that FL protects car-
diomyocytes from oxidative stress–induced apoptosis via
prevention of the Bax/Bcl-2 increase and Akt-dependent
inhibition of cytochrome c release.Discussion
This report provides the ﬁrst evidence that FLT3 represents
an intrinsic cytoprotective system in the heart. Wedemonstrated that cardiomyocytes express FLT3 and serve
as FL target cells. In cultured cardiomyocytes exposed to
oxidative stress, FLT3 expression is up-regulated, and its
activation restores the Bax/Bcl-2 ratio, thus inhibiting
cytochrome c release and apoptosis. FLT3 stimulation with
FL also improves post-myocardial infarction remodeling and
function in vivo, and this outcome is associated with
decreased apoptosis in the infarct border zone. These ﬁnd-
ings identify FLT3 as a potential therapeutic target in
ischemic heart disease. Importantly, they may also provide
a novel mechanistic rationale for the potential contribution
of FLT3 inhibition to the cardiotoxic effects of multi-
targeting TKIs.
FLT3 mRNA has previously been identiﬁed in whole
heart homogenates (5,8) and shown to be up-regulated after
myocardial infarction (8). However, whether intrinsic
cardiac cells or circulating and/or homing extracardiac cells
account for cardiac FLT3 expression was not known. We
found FLT3 mRNA and protein expression in isolated,
cultured cardiomyocytes. Activation of FLT3 with FL
induced a time- and dose-dependent signal and protected
cardiomyocytes against apoptosis. Our ﬁndings, therefore,
strongly support that cardiomyocytes express functional
FLT3 and react to FLT3 stimulation.
FLT3 activation with FL protected cardiomyocytes from
H2O2-induced apoptosis via Akt-dependent inhibition of
cytochrome c release and regulation of Bax/Bcl-2. PI3K/Akt
is an important pathway of cell survival (24), and its acti-
vation is required for survival of acute myeloid leukemia cells
(25). Although a variety of upstream regulators may activate
Akt, constitutive activation of PI3K and Akt is found
in myeloid cells harboring activity-enhancing mutations
of FLT3 such as internal tandem duplications (26). We
observed sustained phosphorylation of Akt in response to
FL and failure of FL to suppress the H2O2-induced cyto-
chrome c release in the presence of the Akt inhibitor VIII,
supporting the theory that Akt is necessary for the anti-
apoptotic effect of FL in cardiomyocytes.
Bcl-2 and in particular the ratio of Bax to Bcl-2 is an
upstream regulator of mitochondrial cytochrome c release
and an important determinant of the cell’s susceptibility to
undergo apoptosis (27). Interestingly, the antiapoptotic
effect of FL has previously been linked to its ability to inhibit
the up-regulation of Bax in acute myeloid leukemia cells
(28). We found a similar effect in cardiomyocytes exposed to
oxidative stress, in which the H2O2-induced increase of Bax
was abolished in the presence of FL. FL also rescued the
decreased expression of Bcl-2 in response to H2O2 in the
pooled cardiomyocyte population, hence restoring the ratio
of Bax to Bcl-2.
Due to their ability to mobilize bone marrow–derived
progenitor cells, combinations of hematopoietic cytokines,
including G-CSF, SCF, and FL, have previously been used
to promote cardiac regeneration in various in vivo models
of ischemic injury (29–31). In particular, the systemic
co-administration of G-CSF and FL over a period of
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101810 days improved left ventricular remodeling and function at
5 weeks after ischemia-reperfusion injury in mice via
a mechanism that involves bone marrow–derived progenitor
cell-mediated cardiac regeneration (31). According to the
distinct hypotheses (i.e., enhanced cardiac regeneration as
opposed to cardioprotection), there are 2 important differ-
ences in design between this study and ours: in the previous
study, FL was administered systemically and over several
days, and used in combination with other cytokines, namely,
G-CSF; we administered FL as a single-dose monotherapy
and also directly into the myocardium adjacent to the area at
risk as demarcated after LAD ligation. This temporally and
spatially restricted application was intended to study the
effects of FL on intrinsic cardiac cells independently from its
mobilizing properties on bone marrow–derived progenitor
cells. Our strategy of FL administration improved cardiac
morphology and function as early as 1 week post-myocardial
infarction and also reduced the infarct size, which was not
seen in the earlier study (31), in which improved remodeling
was observed 5 weeks after myocardial infarction and was
mostly based on enhanced cardiac regeneration. Although
we cannot rule out that FL affected heart-resident progen-
itor cells in our model, our data support the hypothesis that
FL per se acts as a cytoprotective factor in ischemic cardiac
injury and that its method of action includes a direct
protective effect on cardiomyocytes. Interestingly, similar to
FLT3 shown in our study, G-CSFR has recently been
identiﬁed on cardiomyocytes and a direct cardioprotective
effect of G-CSF involving protection of cardiomyocytes
from apoptosis was uncovered (11), which was sufﬁcient to
improve myocardial remodeling and function in the absence
of peripheral cell mobilization.
FLT3 is one of the targets of TKIs used for anticancer
therapy (2), and cardiotoxic effects (including decline in left
ventricular ejection fraction, congestive heart failure, acute
coronary syndrome, and hypertension) occurred in solid
tumor patients treated with TKIs targeting multiple
receptors to inhibit tumor angiogenesis and tumor cell
survival (17–19,32–34). Cardiac dysfunction is among the
most frequent cardiac adverse effects, and it is related to
impaired cardiomyocyte survival due to the suppression of
pro-survival (antiapoptotic) signaling pathways, which
takes effect not only in the cancer cells but also in other
tissues (35). This may include the mitochondrial release of
cytochrome c and apoptotic cardiomyocyte death, which
have been postulated, among others, in response to the
FLT3-targeting TKIs sunitinib and sorafenib (32). Both
sunitinib and sorafenib have multiple targets, and the
upstream mechanisms of enhanced pro-apoptotic signaling
are incompletely understood. Because of the established
roles of vascular endothelial growth factor (36) and platelet-
derived growth factor (37) in the myocardium, inhibition of
their receptors, as well as off-target effects (18,19), have
primarily been held responsible for the cardiotoxicity of
these drugs. The cardioprotective role of FLT3 uncoveredin the present study raises the possibility that FLT3 inhi-
bition may be involved in cardiomyocyte death, particularly
in patients with ischemic heart disease. However, we would
like to emphasize that although we demonstrated an anti-
apoptotic effect of FLT3 activation by exogenous FL in
cardiomyocytes, further studies are needed to establish the
precise roles of endogenous FLT3 signaling in the heart and
to determine whether its inhibition indeed contributes to
cardiotoxicity.
Regarding a potential therapeutic use of FL, it is of note
that FL has previously been applied to humans and has been
well tolerated (38,39). Importantly, neither human nor
animal studies have reported tumorigenic effects of systemic
FL application.
Study limitations. As already pointed out, this study did
not address the role of endogenous FLT3 signaling or the
consequences of its inhibition in the heart. Results from this
pre-clinical study conducted in mice cannot necessarily be
extrapolated to humans.
Conclusions
Our data demonstrate that cardiomyocytes express FLT3 and
provide a functional relevance to this expression. We iden-
tiﬁed FLT3/FL as a cardioprotective system and a potential
therapeutic target that is up-regulated and the activation
thereof is beneﬁcial in cardiac ischemia. The recognition of
FLT3/FL as an innate cytoprotective system in the heart may
offer a novel therapeutic strategy to mitigate ischemic cardiac
injury but also raises concerns about the potential cardio-
toxicity of FLT3-targeting anticancer therapy. Further
mechanistic and clinical studies are needed to explore puta-
tive adverse effects of FLT3 inhibition on the heart, paying
particular attention to subsets of patients with ischemic heart
disease and/or multitargeted combination chemotherapy.Acknowledgments
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